Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Clin Cancer Res. 2014 Dec 5;21(5):985–994. doi: 10.1158/1078-0432.CCR-14-1765

Table 4.

Response by baseline characteristics

Baseline parameter Responders/Evaluable %
Total responders 14/44 32

Prior therapies
 No HMA 1/8 13
 HMA 13/36 36

Baseline cytopenias
 1 2/19 11
 2–3 12/25 48

Prior HMA and 2–3 cytopenias 11/22 50

IPSS risk
 Low 2/12 17
 Intermediate-1 12/32 38

Phospho-p38 MAPK status at Baseline
 Positive1 7/13 54
 Negative2 2/6 33
1

Positive defined as ≥ 5% p-p38[+] cells

2

One patient negative for phospho-p38 MAPK at baseline was not evaluable for HI